In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

The US Food and Drug Administration (FDA) has expanded the approval for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) to include adults with prostate-specific membrane antigen (PSMA ...

Lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) received an expanded indication, which allows the radioligand therapy to be used after one androgen receptor pathway inhibitor (ARPI), as ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...

Pluvicto (lutetium [177Lu] vipivotide tetraxetan), which won FDA approval in 2022, is fast becoming the dominant RLT for prostate cancer, according to GlobalData. The data and analysis firm wrote ...

Novartis said the U.S. Food and Drug Administration has approved the use of Pluvicto against a certain type of prostate cancer. The drug maker said Friday that the FDA green-lit the use of ...